Inhibrx, Inc.

Equities

INBX

US45720L1070

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:01 2024-03-28 pm EDT 5-day change 1st Jan Change
34.96 USD -0.54% Intraday chart for Inhibrx, Inc. -0.03% -8.00%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Inhibrx Shares Fall After Q4 Net Loss Widens MT
Earnings Flash (INBX) INHIBRX Reports Q4 Revenue $1.6M MT
Inhibrx, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Inhibrx, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Arecor Therapeutics hails Arestat as 2023 performance "strong" AN
North American Morning Briefing : S&P 500 Futures Point to Fresh Record on Netflix Results DJ
Health Care Flat After J&J Earnings -- Health Care Roundup DJ
Arecor pleased as investee Inhibrx sells therapy to Sanofi AN
Sector Update: Health Care Stocks Decline Late Afternoon MT
Sector Update: Health Care MT
Sanofi Agrees to Buy Inhibrx' Rare Disease Candidate For Up To $2.2 Billion MT
CAC40: slight decline in the absence of catalysts CF
CAC40: down in the wake of Bunds and US T-Bonds CF
News Highlights : Top Company News of the Day - Tuesday at 11 AM ET DJ
CAC40: falls back below 7,400, Wall-Street reopens unchanged CF
News Highlights : Top Company News of the Day - Tuesday at 9 AM ET DJ
Sector Update: Health Care Stocks Mixed Premarket Tuesday MT
Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Tuesday as Investors Await Earnings Peak MT
Sector Update: Health Care MT
JMP Securities Downgrades Inhibrx to Market Perform From Market Outperform MT
Sanofi to Buy Assets From Inhibrx in Deal Valued at Up to $2.2 Billion -- Update DJ
Sanofi to Acquire Inhibrx for Up to $2.2 Billion MT
European Midday Briefing : Caution Dominates as Focus Back on Big-Name U.S. Earnngs DJ
News Highlights : Top Company News of the Day - Tuesday at 5 AM ET DJ
CAC40: little movement, caution prevails CF
Chart Inhibrx, Inc.
More charts
Inhibrx, Inc. is a clinical-stage biopharmaceutical company, which is focused on developing a broad pipeline of novel biologic therapeutic candidates. The Company’s pipeline is focused on oncology and orphan diseases. Its clinical pipeline includes therapeutic candidates, such as INBRX-101, and INBRX-109. INBRX-101 is an engineered recombinant human alpha-1 antitrypsin fragment crystallizable (AAT-Fc) fusion protein therapeutic candidate that the Company is developing for the treatment of patients with Alpha-1 Antitrypsin Deficiency (AATD) and acute Graft-versus -host-disease (aGvHD). AATD is an inherited disease that causes an increased risk of developing pulmonary disease defined by progressive loss of lung tissue and function and is associated with decreased life expectancy. INBRX-109 is an engineered tetravalent therapeutic candidate targeting death-receptor 5 (DR5), a TNFRSF member, also known as tumor necrosis factor-related apoptosis-inducing ligand or TRAIL receptor 2.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
3
Last Close Price
34.96 USD
Average target price
35.5 USD
Spread / Average Target
+1.54%
Consensus